Secondary Immunodeficiency
Intravenous immunoglobulin (IVIG) can influence the immune system via multiple mechanisms including neutralisation of pathogens and anti-inflammatory effects. Its therapeutic role has expanded...
Is IMBRUVICA®▼ (ibrutinib) the future of CLL treatment?
Trying to achieve the best outcomes for patients with chronic lymphocytic leukaemia (CLL) has always been a compromise between balancing efficacy and toxicity.1 Current treatment options in...
Implications of ECIL-6 for clinicians
During the 2017 12th Annual Fungal Update, held in the Great Hall at St Bartholomew’s Hospital, London, on February 4th, experts reviewed new evidence on the growing threat of antifungal resistance...
Is IMBRUVICA®▼ the future of CLL treatment?
Trying to achieve the best outcomes for patients with chronic lymphocytic leukaemia (CLL) has always been a compromise between balancing efficacy and toxicity.1 Current treatment options in...
Latest evidence on fungal infections
3rd & 4th February 2017, St Bartholomew’s Hospital, London Dr Samir Agrawal, Chair of the Organising Committee, welcomed participants to the 12th Annual Fungal Update in the Great Hall at St...
Ixazomib▼: a novel oral proteasome inhibitor
Multiple myeloma (MM) is a heterogeneous, incurable malignancy, characterised by remissions and subsequent relapses.1,2 MM predominantly affects the elderly, with a median age at diagnosis around 70...
Invasive aspergillosis and mucormycosis
Isavuconazole (Cresemba®), a triazole antifungal, authorised in the EU since October 2015, demonstrated clinical effectiveness in pivotal trials of invasive aspergillosis and mucormycosis, and a...
The next era in multiple myeloma: from trials to clinical practice
Multiple myeloma (MM) is a B-cell neoplasm that results in an expanded plasma cell population within the bone marrow.1 MM accounts for 2% of newly diagnosed cancers in the UK, or about 5500 cases in...
In pursuit of long-term disease control in multiple myeloma
Multiple myeloma (MM) is a heterogeneous disease for which, despite the continuing advances in existing therapies such as the immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), there is...
Second Spring Forum Haemophilia 2015
The 2nd Spring Forum Haemophilia 2015 – ‘New Avenues in Human rFVIII Replacement: Perspectives and Challenges for the Years Ahead’– was held in Berlin, Germany, on 17 and 18 April 2015. The...
